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Abstract
Background: The present of malignant transformation in struma ovarii is exceedingly rare. Malignant struma ovarii
is usually asymptomatic and infrequently diagnosed preoperatively. Because of its rarity, there is no consensus
about diagnosis and management in the literature.
Case presentation: A 40-year-old female presented for her obstetric examination with an incidental finding of a
pelvic mass. Patient was asymptomatic at presentation. A follow-up ultrasound confirmed the presence of a 3-cm
mass in the left adnexa. Patient underwent a cytoreductive surgery (hysterectomy, bilateral salpingectomy and
oophorectomy, omentectomy, appendectomy, and pelvic lymphadenectomy). Histopathology revealed a malignant
struma ovarii with a focus of papillary thyroid carcinoma and the omentum metastasis. The patient with stage FIGO
IIIc received 6 cycles of paclitaxel/carboplatin regimen after surgery. The patient subsequently had a thyroid scan
that was normal with normal thyroid function. At a follow-up of 12 months, she is alive, in good clinical condition,
and disease-free.
Conclusions: Because of the rarity of these tumors and their lack of firm prognostic factors, treatment decisions
should be made individually, based on pathologic and clinical parameters.
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Background
The majority of germ cell tumors are mature cystic tera-
tomas, which account for approximately 15–20 % of all
ovarian tumors [1]. Of these, 15 % contain thyroid tissue
[2, 3]. Struma ovarii is diagnosed when thyroid tissue
comprises more than 50 % of the teratoma [4, 5]. Struma
ovarii accounts for only 2 % of all mature teratomas, and
less than 5 % of struma ovarii present malignant trans-
formation [4, 6, 7]. Owing to malignant struma ovarii
(MSO) rarity, there has been some controversy about
the diagnosis and treatment, and prognosis is difficult to
evaluate.
We report an unusual case of papillary thyroid cancer
in MSO, with metastasis to the omentum. Here, we pre-
sented a review of literature including the clinicopatho-
logic features, differential diagnosis, and management.
Case presentation
A 40-year-old female presented with an incidental find-
ing of a pelvic mass during her obstetric examination
before 6 years. A palpable mass was noted in the left-
sided pelvis on physical examination. The patient did
not have special symptoms and ascites. Abdominal ultra-
sonography (Voluson S8, General Electric Company,
USA) revealed a 3.0 × 3.1 cm mixed echogenicity mass
in the left adnexa, suggestive of an ovarian teratoma.
The data obtained by routine blood, urine, and thyroid
function tests, as well as tumor markers, were in the
normal range. The patient had no history of thyroid
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dysfunction and no family history of ovarian or endocrine
tumors. The patient had no relevant past interventions.
Malignancy could not be excluded.
The patient underwent laparoscopic ovarian cyst
divesting surgery. At exploration, the uterus, right ovary,
and fallopian tube were normal. The left ovary was en-
larged, and a benign-looking white and smooth ovarian
cystic mass was noted. Upon sectioning, the ovarian mass
was partially cystic and grossly resembled papillary tumor.
The peritoneal washing was negative on cytological exam-
ination. An intra-operative frozen and permanent paraffin
section was proved to be a malignant struma ovarii with
multiple foci of papillary thyroid carcinoma (Fig. 1a). In
the papillary thyroid carcinoma focus, papillary thyroid
tissue with increased mitotic activity and ground glass
nuclei, intra-nuclear inclusions were detected. Also, a few
psammoma bodies were identified. The tumor was re-
stricted within the capsule, and vascular invasion was not
identified. Immunohistochemically, tumor cells were
strongly positive for thyroglobulin (Tg), thyroid transcrip-
tion factor-1 (TTF-1), galetin-3, cytokeratin-19 (CK19),
and human bone marrow endothelial cell-1 (HBME-1)
(Fig. 2). Based on all these findings, the diagnosis was pap-
illary thyroid cancer arising within malignant struma
ovarii. Thus, 1 week later, the patient underwent a cytore-
ductive surgery (hysterectomy, bilateral salpingectomy
and oophorectomy, omentectomy, appendectomy, and
pelvic lymphadenectomy). The pathologic examination
showed no metastatic neoplasm was found, except on the
omentum material (Fig. 1b). After surgery, the patient
with stage FIGO IIIc received 6 cycles systemic chemo-
therapy of paclitaxel (175 mg/m2; over 3 h intravenous in-
fusion) plus carboplatin (area under the curve [AUC] = 5;
over 1 h intravenous infusion), given on day 1 of a 21-day
cycle. Patient subsequently had a thyroid scan that was
normal with normal thyroid function.
Discussion
Struma ovarii is a teratoma in which thyroid tissue is
present exclusively or forms a grossly recognizable com-
ponent of a more complex teratoma [8]. The rate of ma-
lignant transformation in struma ovarii is extremely low.
The mean age at diagnosis of MSO was 43 years old [6, 9].
Most cases of MSO are subclinical. Clinical hyperthyroid-
ism manifestations are seen in 5–8 % of the cases [10].
Moreover, insufficient concordance between morphologic
features and clinical outcome in MSO is striking, making
the behavior of these tumors particularly unpredictable
[11]. It is reported that BRAF V600E gene mutations, a
common pathogenesis for all papillary thyroid cancers, re-
gardless of body location, were present in two thirds of
MSO with papillary features [12].
The predominant sites of metastasis were adjacent pelvic
structures, including the contralateral ovary; hematologic
dissemination includes metastases of the lung, bone, liver,
and brain, but metastasis is rare in patients with MSO. In
this case, the patient had omentum metastasis. The reason
is that the tumor can spread via regional lymphatics to pel-
vic and paraaortic lymph nodes and can directly infiltrate
the omentum [11, 13].
Since it is a rare type of germ cell tumor encountered,
there are no uniform diagnostic criteria for MSO. MSO
is most often diagnosed postoperatively. The histopatho-
logical diagnosis adheres to the same criteria used for
thyroid carcinoma: “ground glass” overlapping nuclei
and nuclear grooves, or mitotic activity and vascular in-
vasion [4]. Eighty-five percent of papillary carcinomas
with the characteristics are “ground glass” nuclei. All
pathologic patterns of thyroid gland malignancy may be
found in struma ovarii, and papillary carcinoma is the
most common [14–16]. Immunohistochemical staining
with Tg, HBME-1, and galectin-3, often positive in pap-
illary thyroid carcinoma, can also help confirm the
Fig. 1 H&E staining of malignant struma ovarii tissues. H&E staining (a) showed fibrous cores of tissue lined by neoplastic cells which
contain large overlapping “ground-glass” nuclei characteristic of thyroid papillary carcinoma. b Metastasis to omentum is shown (H&E,
original magnifications ×400)
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diagnosis and are necessary for differential diagnosis
from carcinoid and granulosa cell tumors [17, 18].
The absence of a primary lesion in the thyroid is ne-
cessary to exclude metastatic thyroid carcinoma to the
ovary [4, 11]. The differential diagnosis from thyroid-
type cancers from the thyroid and ovary depends on im-
munohistochemical stains for CK19 and TTF-1, support-
ing the independent existence of two cancers. Besides
family history and a physical examination followed by an
ultrasound of the thyroid gland, it is reported that unique
characteristics on ovarian magnetic resonance imaging
(MRI) might help to differentiate the two diseases.
The optimal treatment regimen for MSO is currently
debated due to the difficulty to distinguish between be-
nign and malign struma ovarii. Most authors advocate
for an aggressive treatment based on TAH/BSO, lymph-
node dissection and omentectomy, followed by adjuvant
therapy, including external radiotheraphy, chemothera-
phy, and thyroid suppression, regardless of the presence
of distant metastases at time of diagnosis.
MSO might be over-treated, and this might impact long
term the quality of life and fertility of affected women.
Thus, conservative treatment such as unilateral oophorec-
tomy should be the choice for patients who wish to fertil-
ity preservation, if pelvic imaging and surgical exploration
do not reveal extra-ovarian disease [9, 19].
In addition, on the basis of the similarities between
MSO and thyroid carcinoma, near-total thyroidectomy
followed by radioactive iodine (I131) should be first-line
therapy for patient with a higher risk of recurrence or
with palindromia [12]. Treatment with thyroxine was
not documented consistently enough to determine its
impact on recurrence rates.
Patients with MSO had an excellent disease-specific
survival rate, regardless of the management strategy
employed. In 2015, Adam et al. published a study that
included 68 patients with MSO [9]. The data indicated
that overall survival rates for all patients were 94.3 % at
10 years and 84.9 % at 20 years, which was in agreement
with the finding by Robboy et al. published in 2009 [20].
After TAH/BSO and chemotherapy, our patient is cur-
rently disease-free for the past 1 year. But long-term
follow-up with thyroglobulin levels is necessary due to re-
ports of increasing recurrence rates.
Conclusions
Based on the rarity of these tumors and their lack of firm
prognostic factors, treatment decisions should be made
individually, based on pathologic and clinical parameters.
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Fig. 2 Immunohistochemical (CK19, galetin-3, HBME-1) staining of malignant struma ovarii tissues. a CK19 was diffuse and strong cytoplasmic
staining in MSO. b MSO showing strong cytoplasmic staining of galectin-3. c MSO with beautiful complex papillae exhibits a HBME-1 membrane
staining pattern (immunohistochemistry, original magnifications ×400)
Zhu et al. World Journal of Surgical Oncology  (2016) 14:17 Page 3 of 4
Acknowledgements
We thank the patient’s families who agreed to publish the clinical data.
Author details
1Department of Gynecological Oncology, Sichuan Cancer Hospital, No. 55,
Section 4, South People’s Road, Chengdu 610041, Sichuan, China.
2Department of Ultrasound, Sichuan Cancer Hospital, Chengdu, Sichuan,
China. 3Department of Gynaecology and Obstetrics, Chengdu First People’s
Hospital, Chengdu, Sichuan, China. 4Department of Pathology, Sichuan
Cancer Hospital, Chengdu, Sichuan, China.
Received: 27 June 2015 Accepted: 11 January 2016
References
1. Willemse PH, Oosterhuis JW, Aalders JG, Piers DA, Sleijfer DT, Vermey A,
et al. Malignant struma ovarii treated by ovariectomy, thyroidectomy, and
131I administration. Cancer. 1987;60:178–82.
2. Kabukcuoglu F, Baksu A, Yilmaz B, Aktumen A, Evren I. Malignant struma
ovarii. Pathol Oncol Res. 2002;8:145–7.
3. Zakhem A, Aftimos G, Kreidy R, Salem P. Malignant struma ovarii: report of
two cases and selected review of the literature. J Surg Oncol. 1990;43:61–5.
4. Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically
malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol
Pathol. 1993;12:333–43.
5. Navarro MD, Tan MA, Lovecchio JL, Hajdu SI. Case report: malignant struma
ovarii. Ann Clin Lab Sci. 2004;34:107–12.
6. DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report
and analysis of cases reported in the literature with focus on survival and
I131 therapy. Gynecol Oncol. 2003;89:543–8.
7. Matsuda K, Maehama T, Kanazawa K. Malignant struma ovarii with
thyrotoxicosis. Gynecol Oncol. 2001;82:575–7.
8. Scully RE. Recent progress in ovarian cancer. Hum Pathol. 1970;1:73–98.
9. Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA. Malignant
struma ovarii: a population-level analysis of a large series of 68 patients.
Thyroid. 2015;25:211–5. doi:10.1089/thy.2014.0328.
10. Schmidt J, Derr V, Heinrich MC, Crum CP, Fletcher JA, Corless CL, et al. BRAF
in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol.
2007;31:1337–43.
11. Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii.
Gynecol Oncol. 1989;32:224–7.
12. Doganay M, Gungor T, Cavkaytar S, Sirvan L, Mollamahmutoglu L. Malignant
struma ovarii with a focus of papillary thyroid cancer: a case report. Arch
Gynecol Obstet. 2008;277:371–3.
13. Chan SW, Farrell KE. Metastatic thyroid carcinoma in the presence of struma
ovarii. Med J Aust. 2001;175:373–4.
14. Gonzalez-Angulo A, Kaufman RH, Braungardt CD, Chapman FC, Hinshaw AJ.
Adenocarcinoma of thyroid arising in struma ovarii (malignant struma
ovarii). Report of two cases and review of the literature. Obstet Gynecol.
1963;21:567–76.
15. Culine S, Lhomme C, Farhat F, Droz JP. Salvage chemotherapy in non-
dysgerminomatous germ cell tumours of the ovary. Eur J Cancer. 1995;
31A:1890–1.
16. Szyfelbein WM, Young RH, Scully RE. Struma ovarii simulating ovarian
tumors of other types. A report of 30 cases. Am J Surg Pathol. 1995;19:21–9.
17. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al.
Immunohistochemical separation of follicular variant of papillary thyroid
carcinoma from follicular adenoma. Endocr Pathol. 2006;17:213–23.
18. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid
hyperplasia and papillary thyroid carcinoma by immunohistochemical
staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathology.
2003;14:55–60.
19. Shaco-Levy R, Peng RY, Snyder MJ, Osmond GW, Veras E, Bean SM, et al.
Malignant struma ovarii: a blinded study of 86 cases assessing which
histologic features correlate with aggressive clinical behavior. Arch Pathol
Lab Med. 2012;136:172–8. doi:10.5858/arpa.2011-0092-OA.
20. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al.
Malignant struma ovarii: an analysis of 88 cases, including 27 with
extraovarian spread. Int J Gynecol Pathol. 2009;28:405–22. doi:10.1097/PGP.
0b013e3181a27777.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhu et al. World Journal of Surgical Oncology  (2016) 14:17 Page 4 of 4
